Tighter safety expectations, shorter development timelines, more complex active pharmaceutical ingredients (APIs) and growing regulatory support for continuous production are all pushing producers to reconsider how chemistry is done at scale.
That shift has brought continuous production into sharper focus. In pharmaceutical and fine chemical settings, where systems are often smaller and more adaptable, this is usually discussed as flow chemistry.
Once seen as a specialist or secondary approach, it is now moving into the mainstream as manufacturers look for safer, faster and more controllable ways to design and run their processes.
Katrin Schmidt (pictured), Business Development Manager, EMEA, at Evonik, reports.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
